- Home
- CLNE vs YMAB Comparison
CLNE vs YMAB Comparison
Compare CLNE & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLNE
- YMAB
- Stock Information
- Founded
- CLNE 2001
- YMAB 2015
- Country
- CLNE United States
- YMAB United States
- Employees
- CLNE N/A
- YMAB N/A
- Industry
- CLNE Natural Gas Distribution
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- CLNE Utilities
- YMAB Health Care
- Exchange
- CLNE Nasdaq
- YMAB Nasdaq
- Market Cap
- CLNE 448.6M
- YMAB 386.7M
- IPO Year
- CLNE 2007
- YMAB 2018
- Fundamental
- Price
- CLNE $2.64
- YMAB $8.55
- Analyst Decision
- CLNE Strong Buy
- YMAB Buy
- Analyst Count
- CLNE 5
- YMAB 10
- Target Price
- CLNE $3.59
- YMAB $13.91
- AVG Volume (30 Days)
- CLNE 2.1M
- YMAB 2.2M
- Earning Date
- CLNE 08-07-2025
- YMAB 08-08-2025
- Dividend Yield
- CLNE N/A
- YMAB N/A
- EPS Growth
- CLNE N/A
- YMAB N/A
- EPS
- CLNE N/A
- YMAB N/A
- Revenue
- CLNE $420,579,000.00
- YMAB $85,385,000.00
- Revenue This Year
- CLNE $1.46
- YMAB N/A
- Revenue Next Year
- CLNE $2.46
- YMAB $13.97
- P/E Ratio
- CLNE N/A
- YMAB N/A
- Revenue Growth
- CLNE 4.08
- YMAB N/A
- 52 Week Low
- CLNE $1.30
- YMAB $3.55
- 52 Week High
- CLNE $3.67
- YMAB $16.11
- Technical
- Relative Strength Index (RSI)
- CLNE 67.53
- YMAB 81.20
- Support Level
- CLNE $2.35
- YMAB $8.50
- Resistance Level
- CLNE $2.70
- YMAB $8.56
- Average True Range (ATR)
- CLNE 0.12
- YMAB 0.02
- MACD
- CLNE 0.02
- YMAB -0.11
- Stochastic Oscillator
- CLNE 86.44
- YMAB 80.00
About CLNE Clean Energy Fuels Corp.
Clean Energy Fuels Corp is a natural gas marketer and retailer operating in the United States and Canada. The company supplies compressed natural gas, liquefied natural gas for the United States (U.S.) and Canadian transportation markets. The majority of revenue is generated within the U.S. and mostly consists of compressed natural gas. The company operates by purchasing natural gas from local utilities; compressing, cooling, or liquefying it at company-owned plants; and selling natural gas products through company-owned or customer-owned fueling stations. The company also builds, operates, and maintains natural gas fueling stations for customers. The company's target markets include heavy-duty trucking, airports, public transit, institutional energy users, and government fleets.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.